A two-trial repeated measures design will be employed in this investigation. Both the control trial and the exercise trial will last for 3 months. During a week before the start of the study, participants will complete dietary recalls and record their habitual physical activity using accelerometers. Thereafter, body composition, ultrasound imaging of the muscle and liver, biochemical and hematological markers were measured. This range of measurements will be repeated the ended each month for both trials. Control trial succeeds exercise trial. An exercise intervention program will take place in the second trial, three times a week.
A sample size of 30 volunteers, aged 35-45 years, will participate in the present study. Of them, 15 will be normal weight and 15 will suffer from fatty liver disease (BMI 29-35 kg/m2, waist size \>102 cm). The exclusion criteria will be a) medication, b) musculoskeletal problems that will prevent participation in the training program, c) known condition or medical condition preventing participation in the program e.g. hypertension, d) BMI\> 35kg / m2, (e) a severe family medical history up to first degree relatives with cardiovascular disease and / or diabetes at the age of less than 65 for women and less than 55 years for men and (f) smoking. After informing and receiving a questionnaire and medical history, volunteers will sign for their participation in the survey. A two-trial repeated measures design will be applied in this investigation. Both control and exercise trials will last for 3 months. During the week preceding the commencement of the study, participants will complete dietary recalls and will have their habitual physical activity monitored, by utilizing accelerometers. Thereafter, body composition, ultrasound imaging of muscle and liver, biochemical and hematological markers will be measured. The same measurements will be repeated at the end of each month, in both trials. Control trial will be executed prior to exercise trial. An exercise intervention program, combining strength and cardiovascular exercises performed three times a week, will take place in the exercise trial.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Participants will abstain from exercise throughout a 3-month period
Participants will execute a 3-month exercise training program
Democritus University of Thrace, School of Physical Education and Sports Science
Komotini, Greece
Changes in body composition
Body composition will be assessed using Dual-energy-X-ray Absorptiometry (DXA) instrumentation
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in HDL concentration
HDL concentration will be measured in blood
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in LDL concentration
LDL concentration will be measured in blood
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in total cholesterol
Total cholesterol levels will measured in blood
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in triglycerides
Triglycerides concentration will be measured in blood
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in free fatty acids
Free fatty acid concentration will be measured in blood
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in glucose
Glucose concentration will be measured in blood
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in glycosylated hemoglobin
Glycosylated hemoglobin levels will be measured in blood
Time frame: At baseline as well as at 1,5 and 3 months in both trials
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Masking
NONE
Enrollment
20
Changes in insulin
Insulin concentration will be measured in blood
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in insulin resistance index
Insulin resistance index will be calculated through glucose and insulin values
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in White Blood Cells
White blood cells will be measured in bood samples
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in Red Blood Cells
Red blood cells will be measured in bood samples
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in Hemoglobin
Hemoglobin will be measured in blood samples
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in Hematocrit
Hematocrit levels will be measured in blood samples
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in transaminases
Transaminase levels will be measured in blood samples
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in C-reactive protein
C-reactive protein levels will be measured in blood samples
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in total antioxidant capacity
Total antioxidant capacity will be assessed in plasma
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in glutathione
Oxidized (GSH) and reduced (GSSG) glutathione will be measured in red blood cell lysate
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in protein carbonyls
Protein carbonyl formation will be measured in serum
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in thiobarbituric acid reactive substances (TBARS)
TBARS will be measured in serum
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in catalase
Catalase activity will be measured in serum
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in fatty infiltration of the liver
Fatty infiltration of the liver will be assessed by ultrasound imaging of liver
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in bone status
Bone mineral density and bone mineral content will be assessed in hole body, spine and hips using DXA
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in body weight
Time frame: At baseline as well as at 1,5 and 3 months in both trials
Changes in muscle architecture
Muscle architecture of quadriceps will be assessed by ultrasonography
Time frame: At baseline as well as at 1,5 and 3 months in both trials